Personalized Integrated Network Modeling of the Cancer Proteome Atlas

Personalized (patient-specific) approaches have recently emerged with a precision medicine paradigm that acknowledges the fact that molecular pathway structures and activity might be considerably different within and across tumors. The functional cancer genome and proteome provide rich sources of information to identify patient-specific variations in signaling pathways and activities within and across tumors; however, current analytic methods lack the ability to exploit the diverse and multi-layered architecture of these complex biological networks. We assessed pan-cancer pathway activities for >7700 patients across 32 tumor types from The Cancer Proteome Atlas by developing a personalized cancer-specific integrated network estimation (PRECISE) model. PRECISE is a general Bayesian framework for integrating existing interaction databases, data-driven de novo causal structures, and upstream molecular profiling data to estimate cancer-specific integrated networks, infer patient-specific networks and elicit interpretable pathway-level signatures. PRECISE-based pathway signatures, can delineate pan-cancer commonalities and differences in proteomic network biology within and across tumors, demonstrates robust tumor stratification that is both biologically and clinically informative and superior prognostic power compared to existing approaches. Towards establishing the translational relevance of the functional proteome in research and clinical settings, we provide an online, publicly available, comprehensive database and visualization repository of our findings (https://mjha.shinyapps.io/PRECISE/).

[1]  P. Sorger,et al.  Sequential Application of Anticancer Drugs Enhances Cell Death by Rewiring Apoptotic Signaling Networks , 2012, Cell.

[2]  Prahlad T. Ram,et al.  A pan-cancer proteomic perspective on The Cancer Genome Atlas , 2014, Nature Communications.

[3]  Alfonso Valencia,et al.  EnrichNet: network-based gene set enrichment analysis , 2012, Bioinform..

[4]  Eli Upfal,et al.  Algorithms for Detecting Significantly Mutated Pathways in Cancer , 2010, RECOMB.

[5]  William C. Hahn,et al.  Towards systematic functional characterization of cancer genomes , 2011, Nature Reviews Genetics.

[6]  Seon-Young Kim,et al.  PAGE: Parametric Analysis of Gene Set Enrichment , 2005, BMC Bioinform..

[7]  Markus List,et al.  KeyPathwayMinerWeb: online multi-omics network enrichment , 2016, Nucleic Acids Res..

[8]  Yiling Lu,et al.  Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays. , 2017, Cancer cell.

[9]  Marino E. Leon,et al.  Tumor-to-Tumor Metastasis: Renal Cell Carcinoma Metastatic to Papillary Carcinoma of Thyroid—Report of a Case and Review of the Literature , 2009, Head and neck pathology.

[10]  Peng Qiu,et al.  TCGA-Assembler: open-source software for retrieving and processing TCGA data , 2014, Nature Methods.

[11]  Jan Baumbach,et al.  De novo pathway-based biomarker identification , 2017, Nucleic acids research.

[12]  Pooja Mittal,et al.  A novel signaling pathway impact analysis , 2009, Bioinform..

[13]  K. Kinzler,et al.  Cancer genes and the pathways they control , 2004, Nature Medicine.

[14]  Steven J. M. Jones,et al.  Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. , 2015, The New England journal of medicine.

[15]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[16]  Andrew M. Gross,et al.  Network-based stratification of tumor mutations , 2013, Nature Methods.

[17]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.

[19]  David Haussler,et al.  Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM , 2010, Bioinform..

[20]  J. Berger,et al.  Optimal predictive model selection , 2004, math/0406464.

[21]  Andrea Califano,et al.  Rewiring makes the difference , 2011, Molecular systems biology.

[22]  Sourav Bandyopadhyay,et al.  Rewiring of Genetic Networks in Response to DNA Damage , 2010, Science.

[23]  David Venet,et al.  Most Random Gene Expression Signatures Are Significantly Associated with Breast Cancer Outcome , 2011, PLoS Comput. Biol..

[24]  Aleix Prat Aparicio Comprehensive molecular portraits of human breast tumours , 2012 .

[25]  T. Pawson,et al.  Oncogenic re-wiring of cellular signaling pathways , 2007, Oncogene.

[26]  Amin Allahyar,et al.  FERAL: network-based classifier with application to breast cancer outcome prediction , 2015, Bioinform..

[27]  Peter J. Woolf,et al.  GAGE: generally applicable gene set enrichment for pathway analysis , 2009, BMC Bioinformatics.

[28]  R. Peck,et al.  The right dose for every patient: a key step for precision medicine , 2015, Nature Reviews Drug Discovery.

[29]  N. Meinshausen,et al.  Stability selection , 2008, 0809.2932.

[30]  David Haussler,et al.  PARADIGM-SHIFT predicts the function of mutations in multiple cancers using pathway impact analysis , 2012, Bioinform..

[31]  M. Tuveri,et al.  Renal cell carcinoma metastasis to thyroid tumor: a case report and review of the literature , 2013, Journal of Medical Case Reports.

[32]  Jan Baumbach,et al.  On the performance of de novo pathway enrichment , 2017, npj Systems Biology and Applications.

[33]  Peter Bühlmann,et al.  Causal stability ranking , 2011, Bioinform..

[34]  Joshua M. Stuart,et al.  The Cancer Genome Atlas Pan-Cancer analysis project , 2013, Nature Genetics.

[35]  M. Horattas,et al.  Metastatic renal cell carcinoma to the thyroid gland. , 2008, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[36]  Tobias Müller,et al.  Bioinformatics Applications Note Systems Biology Bionet: an R-package for the Functional Analysis of Biological Networks , 2022 .

[37]  Cheng Li,et al.  Adjusting batch effects in microarray expression data using empirical Bayes methods. , 2007, Biostatistics.

[38]  Rehan Akbani,et al.  Integrated Molecular Characterization of Uterine Carcinosarcoma. , 2017, Cancer cell.

[39]  M. Stratton,et al.  Clinical and biological implications of driver mutations in myelodysplastic syndromes. , 2013, Blood.

[40]  J. Brugarolas PBRM1 and BAP1 as novel targets for renal cell carcinoma. , 2013, Cancer journal.

[41]  Francesco C Stingo,et al.  Bayesian nonlinear model selection for gene regulatory networks , 2015, Biometrics.

[42]  Peter Bühlmann,et al.  Estimating High-Dimensional Directed Acyclic Graphs with the PC-Algorithm , 2007, J. Mach. Learn. Res..

[43]  Steven J. M. Jones,et al.  Integrated Genomic Characterization of Papillary Thyroid Carcinoma , 2014, Cell.

[44]  Robert Tibshirani,et al.  Estimating the number of clusters in a data set via the gap statistic , 2000 .

[45]  Tso-Jung Yen,et al.  Discussion on "Stability Selection" by Meinshausen and Buhlmann , 2010 .